EXELIXIS
Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, ... although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.
EXELIXIS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1994-01-01
Address:
Alameda, California, United States
Country:
United States
Website Url:
http://www.exelixis.com
Total Employee:
251+
Status:
Active
Contact:
+1 6508378300
Total Funding:
379 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Font Awesome Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2004-10-19 | X-Ceptor Therapeutics, Inc. | X-Ceptor Therapeutics, Inc. acquired by Exelixis | N/A |
| 2001-11-20 | Genomica S.A.U. | Genomica S.A.U. acquired by Exelixis | 110 M USD |
| 2001-04-23 | TaconicArtemis GmbH | TaconicArtemis GmbH acquired by Exelixis | N/A |
| 2000-09-08 | Agritope | Agritope acquired by Exelixis | 68 M USD |
| 1999-07-12 | Metaxen LLC | Metaxen LLC acquired by Exelixis | N/A |
Investors List
Deerfield
Deerfield investment in Post-IPO Debt - Exelixis
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Exelixis
Deerfield
Deerfield investment in Post-IPO Debt - Exelixis
PaineWebber
PaineWebber investment in Seed Round - Exelixis
Atlas Venture
Atlas Venture investment in Seed Round - Exelixis
Oxford Bioscience Partners
Oxford Bioscience Partners investment in Seed Round - Exelixis
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-04 | Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer |
Official Site Inspections
http://www.exelixis.com Semrush global rank: 754.17 K Semrush visits lastest month: 53.31 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Exelixis"
Leadership Team l Exelixis
At Exelixis, we don’t simply have a mission, we are on a mission. This global ambition fuels our collaborative team committed to fulfilling our promise of oncology innovation excellence. By putting patient and employee needs at the …See details»
Advancing Science for Cancer Treatments l Exelixis
Exelixis is on a mission to help cancer patients recover stronger and live longer. Our Story. Cancer is our cause — make it yours too. Evolving cancer care begins with you. We offer purposeful career growth opportunities and a vibrant culture …See details»
Exelixis - Wikipedia
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. I…See details»
Exelixis - The Org
Exelixis strives to deliver results and new medicines to treat and defeat cancer, giving patients hope for the future.See details»
Exelixis' Leadership Team Team - Team members and org chart
The leadership team at Exelixis has a strong background in finance and molecular biology. They have held positions at large pharmaceutical companies such as Gilead Sciences and Wyeth …See details»
Exelixis - Leadership Team - The Org
The Leadership Team at Exelixis is responsible for guiding the strategic direction of the company, ensuring alignment with its mission to develop innovative cancer therapies. This diverse group …See details»
Exelixis - Crunchbase Company Profile & Funding
Exelixis Inc reported strong revenue growth and an expanding pipeline in Q4 and FY 2023. The company also beat analyst estimates in one of its earnings reports, although it missed …See details»
Investors and News | Exelixis
Oct 14, 2024 Exelixis is expanding its global innovation engine to evolve how cancer is treated and deliver for physicians, patients and partners. Stock quote. Exelixis, Inc. Volume: Data as …See details»
Exelixis - LinkedIn
Exelixis | 53,201 followers on LinkedIn. Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the ...See details»
Building a Legacy of Oncology Excellence l Exelixis
The Exelixis story began in 1994 when our prominent team of founding scientists set out to use model system genetics to systematize drug discovery. This vision ultimately resulted in our flagship commercial product, CABOMETYX ® …See details»
CEO and Executive Team - The Org
The executive team at Exelixis has experience in finance and the pharmaceutical industry. The executive team at Exelixis has experience in finance and the pharmaceutical industry. ... The …See details»
Exelixis, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
May 1, 2023 Explore Exelixis, Inc. with its drug pipeline, therapeutic area, technology platform, 129 clinical trials, 296 news, and 460 literature, Disease Domain:Neoplasms, Hemic and …See details»
Exelixis Company Profile - Office Locations, Competitors ... - Craft
Oct 25, 2024 Exelixis is a genomics-based drug discovery company and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary …See details»
Exelixis Provides Regulatory Update Related to Supplemental New …
6 days ago ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 26, 2024-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the …See details»
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on …
Dec 7, 2023 ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 7, 2023-- Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy …See details»
Making a Difference Goes Beyond Developing Medicines l Exelixis
Supporting nonprofit organizations is a critical component of how we bring our mission to life at Exelixis. The advocacy community complements the work we are doing to innovate new …See details»
Paige Mahaney - SVP And Head Of Drug Discovery Research at …
Paige currently holds the role of SVP and Head of Drug Discovery Research at Exelixis since June 2021. Prior to that, they served as a Scientific Advisory Board Member at Eurofins …See details»
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It
3 days ago A month has gone by since the last earnings report for Exelixis (EXEL). Shares have added about 10.8% in that time frame, outperforming the S&P 500. Will the recent positive …See details»
Sustainability at Exelixis
To that end, each Exelixis employee is expected to commit to the highest standards of ethical behavior and maintain values and principles that reflect both global awareness and …See details»